Clinical trial NCT05203796: The Evaluation of the Transcutaneous Electrical Stimulation Medical Device's Safety and Effectiveness in Treating the Patients With Dry Eye Disease
Official title: A Single-centered, Double-blinded, Placebo/Sham-controlled, Randomized Exploratory Clinical Trial to Evaluate the Transcutaneous Electrical Stimulation Medical Device's Safety and Effectiveness in Treating the Patients With Mild- or Moderate-level Dry Eye Disease Using NuEyne 02 (Personal Stimulator)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye Disease
Lead sponsor: Nu Eyne Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2022-01-24
Enrollment: 24
Sex: ALL
Minimum age (years): 19
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the safety and effectiveness for applying the electrical stimulation transcutaneously around the eyes and peripheral nerves nearby. The outcomes are compared between the patients with mild- or moderate-level dry eye disease using the real electrical stimulator and the sham electrical stimulator.

Detailed description: Duration of study period(per participant): Screening period (0-4weeks), Intervention period (5weeks).

Patient needs to visit site at least 3 times (Screening, V4, V6), V2 can be done with screening visit.

The clinical trial device performs a personal electrical stimulator around the eyes and peripheral nerves for 28 days (7 times/week, 30 minutes each time).

During the study period, dry eye examination and treatment methods (only eye drops provided in clinical trials are applied) are carried out in the same way.

Eligibility criteria: Inclusion Criteria:

* Men and women aged 19 to 70 years old
* Those who are diagnosed with dry eyes at the time of screening and have complained of dry eyes, discomfort, foreign body sensation, pain, and changes in vision for more than three months.
* Patients with OSDI score of 23 or more
* Patients with Fluorescein corneal staining score of 4 or more
* Schirmer test I result is less than 10mm for 5 minutes
* TBUT (Tear film break up time) test result of less than 10 seconds
* Those who agree not to use eye drops other than artificial tears provided in this clinical trial during the clinical trial period
* A person who voluntarily agreed to participate in this clinical trial

Exclusion Criteria:

* Those who participated in other clinical trials within 30 days of screening.
* Those who applied medical devices to treat dry eye syndrome and IPL medication such as cyclosporin for treatment of dry eye syndrome and local steroid eye drops within one month from the screening date.
* Those who have worn contact lenses within 72 hours prior to screening or need to wear contact lenses during the clinical trial period
* Patients with a history of ophthalmic surgery within 3 months before screening.
* Those with a history of vision correction surgery (LASIK, LASEK), etc. within 6 months from the screening date
* Patients who received a lacrimal punctual occlusion or a tear point cauterization of the within 90 days of screening.
* Patients with symptoms of anterior uveitis or active blepharitis.
* Patients currently receiving treatment for allergic eye disease
* Patients with an abnormality of the eyelid structure
* Patients with moderate to severe meibomian gland disorders
* Those with underlying diseases such as glaucoma, burns, Steven Johnson Syndrome, vitamin A deficiency-related diseases, thyroid dysfunction-related diseases, and neurotropic keratinis.
* Other clinically significant ophthalmic diseases that are not caused by dry eye disease After corneal transplant surgery, corneal surface disease, abnormal corneal sensitivity, abnormal tear excess, etc. may confuse the interpretation of clinical trial results.
* Patients with uncontrolled systemic chronic diseases such as diabetes) or a history of malignant tumors
* Autoimmune disease patients
* People taking medications such as Steroids, immunosuppressants, omega 3 and anticholinergic drugs, etc.
* Pregnant or lactating women
* Among female subjects of childbearing potential, those who do not consent to contraception by a medically accepted method during this clinical trial period
* Medically permitted contraceptive methods: condoms, oral contraceptives that last at least three months, injections or insertion contraceptives, and installation of intrauterine contraceptives, etc.
* Patients with a history of drug or alcohol abuse
* People who are allergic to medicines such as Fluorescein Solution or eye drop anesthetics
* A person who is judged to have a problem in electrode attachment due to an inflammatory reaction or other dermatological problems in the periorbital skin where the electrode of the medical device for clinical trial is attached
* A person who is judged to have other reasons for prohibiting the use of medical devices for clinical trials
* Any other cases that PI considers hard to participate in this clinical trial(e.g. heart-related problems, seizure, epilepsy. Patients transplanted metal or electronic device in head \& neck. Patient suffering from unknown pain. Patients who are warned not to use out clinical trial device or is prohibited from using it.)

Primary outcomes:
measure: Changes in Tear Break-Up Time(TBUT)
timeFrame: baseline, 2, 4 weeks
measure: Changes in Corneal & Conjunctival Fluorescein staining score
timeFrame: baseline, 2, 4 weeks
Secondary outcomes:
measure: Changes in Ocular Surface Disease Index Dry Eye Questionnaires(OSDI) score
timeFrame: baseline, 2, 4 weeks
measure: Changes in A Five-item Dry Eye Questionnaire(DEQ-5) score
timeFrame: baseline, 2, 4 weeks
measure: Changes in Visual Analog Scale(VAS) score
timeFrame: baseline, 2, 4 weeks
measure: Changes in Matrix Metalloproteinases-9(MMP-9) level
timeFrame: baseline, 2, 4 weeks
measure: Changes in Tear Lipid Layer Thickness as measured by Lipiview
timeFrame: baseline, 2, 4 weeks
measure: Changes in Tear Volume as measured by Schirmer's Test
timeFrame: baseline, 2, 4 weeks
measure: Changes in Tear Osmolarity
timeFrame: baseline, 2, 4 weeks
measure: Changes in Corneal Sensitivity as measured by aesthesiometer
timeFrame: baseline, 2, 4 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Ophthalmology, Samsung Medical Center
Study officials:
affiliation: donghui.lim@samsung.com
name: Donghui Lim, Ph. D., MD.
role: PRINCIPAL_INVESTIGATOR
References: